GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (NYSE:GKOS) » Definitions » Cyclically Adjusted Price-to-FCF

Glaukos (Glaukos) Cyclically Adjusted Price-to-FCF : (As of Apr. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Glaukos Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Glaukos Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Glaukos's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos Cyclically Adjusted Price-to-FCF Chart

Glaukos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Glaukos Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Glaukos's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, Glaukos's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Glaukos's Cyclically Adjusted Price-to-FCF falls into.



Glaukos Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Glaukos's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Glaukos's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.304/129.4194*129.4194
=-0.304

Current CPI (Dec. 2023) = 129.4194.

Glaukos Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.195 99.695 -0.253
201406 -0.051 100.560 -0.066
201409 -0.003 100.428 -0.004
201412 -0.072 99.070 -0.094
201503 -0.042 99.621 -0.055
201506 -0.045 100.684 -0.058
201509 -0.023 100.392 -0.030
201512 -0.029 99.792 -0.038
201603 -0.037 100.470 -0.048
201606 0.144 101.688 0.183
201609 0.025 101.861 0.032
201612 0.033 101.863 0.042
201703 0.041 102.862 0.052
201706 0.087 103.349 0.109
201709 0.122 104.136 0.152
201712 0.307 104.011 0.382
201803 -0.222 105.290 -0.273
201806 0.088 106.317 0.107
201809 0.102 106.507 0.124
201812 0.265 105.998 0.324
201903 -0.012 107.251 -0.014
201906 0.130 108.070 0.156
201909 -0.108 108.329 -0.129
201912 -0.098 108.420 -0.117
202003 -0.317 108.902 -0.377
202006 -0.308 108.767 -0.366
202009 -0.243 109.815 -0.286
202012 0.188 109.897 0.221
202103 -0.284 111.754 -0.329
202106 -0.086 114.631 -0.097
202109 0.160 115.734 0.179
202112 -0.298 117.630 -0.328
202203 0.064 121.301 0.068
202206 -0.456 125.017 -0.472
202209 -0.684 125.227 -0.707
202212 -0.259 125.222 -0.268
202303 -0.787 127.348 -0.800
202306 -0.288 128.729 -0.290
202309 -0.237 129.860 -0.236
202312 -0.304 129.419 -0.304

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Glaukos  (NYSE:GKOS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Glaukos Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Glaukos's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Glaukos (Glaukos) Business Description

Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Executives
Alex R. Thurman officer: SVP & Chief Financial Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Joseph E Gilliam officer: CFO, SVP Corporate Development C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677
Thomas William Burns director, 10 percent owner, officer: Chief Executive Officer C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Marc Stapley director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Gilbert H Kliman director C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Tomas Navratil officer: Chief Development Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Leana Wen director C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Chris M. Calcaterra officer: Chief Commercial Officer C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Jonathan Silverstein director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard L Harrison officer: Treasurer, CFO & Secretary 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022